Supernus Pharma (SUPN) Misses Q1 EPS by 2c

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.29, $0.02 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $153.76 million versus the consensus estimate of $137.74 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• OMNIQ Corp. posts Q2 2026 revenue of $7.4M, widens net loss
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance